

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

Karpas-299

RRID:CVCL_1324

Type: Cell Line

Proper Citation

RRID:CVCL_1324

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1324

Proper Citation: RRID:CVCL_1324

Description: Cell line Karpas-299 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Anaplastic large cell lymphoma, ALK-positive

Defining Citation: [PMID:3260522](#), [PMID:8558920](#), [PMID:9738977](#), [PMID:9787181](#), [PMID:11021758](#), [PMID:11494142](#), [PMID:15356658](#), [PMID:17170727](#), [PMID:20164919](#), [PMID:20922763](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:26589293](#), [PMID:26657151](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28356514](#), [PMID:29899875](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Karpas-299

Synonyms: KARPAS-299, Karpas 299, KARPAS 299, Karpas299, KARPAS299, K299

Cross References: BTO:BTO_0002829, CLO:CLO_0007065, EFO:EFO_0005390, CLDB:cl2995, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:624, BioSample:SAMN03473348, BioSample:SAMN10988031, cancercellines:CVCL_1324,

Cell_Model_Passport:SIDM01010, ChEMBL-Cells:CHEMBL3308327, ChEMBL-Targets:CHEMBL2366156, Cosmic:850199, Cosmic:907273, Cosmic:1086364, Cosmic:1086752, Cosmic:1509203, Cosmic:1995466, Cosmic:2674498, Cosmic-CLP:907273, DepMap:ACH-000053, DSMZ:ACC-31, DSMZCellDive:ACC-31, ECACC:06072604, EGA:EGAS00001000978, GDSC:907273, GEO:GSM887195, GEO:GSM888268, GEO:GSM1217153, GEO:GSM1669975, IARC_TP53:21427, LiGeA:CCLE_563, LINCS_LDP:LCL-1117, Lonza:18, PharmacDB:KARPAS299_729_2019, PRIDE:PXD030304, Progenetix:CVCL_1324, PubChem_Cell_line:CVCL_1324, Wikidata:Q54899495, Ximbio:152418

ID: CVCL_1324

Record Creation Time: 20220427T220657+0000

Record Last Update: 20260905T180926+0000

Ratings and Alerts

No rating or validation information has been found for Karpas-299.

Warning: Discontinued: DSMZ; ACC-31

Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. Nature communications, 17(1), 759.

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. bioRxiv : the preprint server for biology.

Billon E, et al. (2025) BTN2A1 acquisition through trogocytosis enhances V γ V δ T cell cytotoxicity against autologous and cancer cells. Cell reports, 44(10), 116387.

Abdelhamed S, et al. (2025) PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors. *Molecular cancer therapeutics*, 24(7), 963.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.

Coats JT, et al. (2024) Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition. *Cancer research communications*, 4(11), 3013.

Liu P, et al. (2024) Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma. *American journal of cancer research*, 14(6), 2921.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. *Cancer research communications*, 4(6), 1441.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. *Molecular cancer therapeutics*, 23(1), 68.

Nava Lauson CB, et al. (2023) Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. *Cell metabolism*, 35(4), 633.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Kim J, et al. (2022) KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells. *Cell reports*, 40(3), 111077.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Muliaditan T, et al. (2021) Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. *Cell reports. Medicine*, 2(12), 100457.